Journal article

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Abstract:: Background Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites.

Methods We did a double-blind, randomised, phase 3 trial of t...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J.-B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., … Hill, A. V. S. (2024). Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet, 403(10426), 533–544.

MLA Style

Datoo, MS, et al. “Safety and Efficacy of Malaria Vaccine Candidate R21/Matrix-M in African Children: a Multicentre, Double-Blind, Randomised, Phase 3 Trial.” Lancet, vol. 403, no. 10426, 2024, pp. 533–44.

Chicago Style

Datoo, MS, A Dicko, H Tinto, et al. 2024. “Safety and Efficacy of Malaria Vaccine Candidate R21/Matrix-M in African Children: a Multicentre, Double-Blind, Randomised, Phase 3 Trial.” Lancet 403 (10426): 533–44.
Print

Access Document

Files:: Datoo_et_al_2024_Safety_and_efficacy.pdf

(Preview, Version of record, pdf, 451.2KB, Terms of use)

Publisher copy:: 10.1016/S0140-6736(23)02511-4

Authors

+ Datoo, MS More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author
ORCID:: 0000-0003-4968-2842

+ Dicko, A More by this author

Role:: Author

+ Tinto, H More by this author

Role:: Author

+ Ouédraogo, J-B More by this author

Role:: Author

+ Hamaluba, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Tropical Medicine
Sub unit:: Centre for Tropical Medicine and Global Health at Oxford
Role:: Author

More authors...

Contributors

+ R21/Matrix-M Phase 3 Trial Group

Role:: Contributor

+ Serum Institute of India More from this funder

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 403
Issue:: 10426
Pages:: 533-544
Place of publication:: England
Publication date:: 2024-02-01
Acceptance date:: 2023-11-06
DOI:: 10.1016/S0140-6736(23)02511-4
EISSN:: 1474-547X
ISSN:: 0140-6736
Pmid:: 38310910

Language:: English
Keywords:: R21/Matrix-M Phase 3 Trial Group
Pubs id:: 1616263
Local pid:: pubs:1616263
Deposit date:: 2024-03-12
ARK identifier:: ark:/29072/ora_45fa32fbbb0a47e09c7e9337635e57ec

Terms of use

Copyright holder:: Datoo et al.
Copyright date:: 2024
Rights statement:: © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC license.

Licence:: CC Attribution-NonCommercial (CC BY-NC)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP